Ignite Creation Date:
2025-12-24 @ 2:15 PM
Ignite Modification Date:
2026-01-04 @ 2:53 AM
Study NCT ID:
NCT05207995
Status:
COMPLETED
Last Update Posted:
2025-12-02
First Post:
2021-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 32}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-03-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2023-12-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-01', 'studyFirstSubmitDate': '2021-11-29', 'studyFirstSubmitQcDate': '2022-01-12', 'lastUpdatePostDateStruct': {'date': '2025-12-02', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-01-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The glucose concentration in blood', 'timeFrame': '1 month', 'description': 'To assess the glucose concentration in blood'}, {'measure': 'The glycated hemoglobin concentration', 'timeFrame': '1 month', 'description': 'To assess the β-cell function measured by the glycated hemoglobin in blood'}, {'measure': 'The C-peptide level in blood', 'timeFrame': '1 month', 'description': 'To assess the β-cell function measured by the C-peptide level'}, {'measure': 'The glucose concentration in blood', 'timeFrame': '6 months', 'description': 'To assess the glucose concentration in blood'}, {'measure': 'The glycated hemoglobin concentration', 'timeFrame': '6 months', 'description': 'To assess the β-cell function measured by the glycated hemoglobin in blood'}, {'measure': 'The C-peptide level in blood', 'timeFrame': '6 months', 'description': 'To assess the β-cell function measured by the C-peptide level'}, {'measure': 'The glucose concentration in blood', 'timeFrame': '1 year', 'description': 'To assess the glucose concentration in blood'}, {'measure': 'The glycated hemoglobin concentration', 'timeFrame': '1 year', 'description': 'To assess the β-cell function measured by the glycated hemoglobin in blood'}, {'measure': 'The C-peptide level in blood', 'timeFrame': '1 year', 'description': 'To assess the β-cell function measured by the C-peptide level'}, {'measure': 'Autoantigen specific T cell count', 'timeFrame': '1 month', 'description': 'To determine the autoantigen specific T cell count using the flow cytometry'}, {'measure': 'Autoantigen specific T cell count', 'timeFrame': '6 months', 'description': 'To determine the autoantigen specific T cell count using the flow cytometry'}, {'measure': 'Autoantigen specific T cell count', 'timeFrame': '1 year', 'description': 'To determine the autoantigen specific T cell count using the flow cytometry'}, {'measure': 'Adverse effects associated with the therapy', 'timeFrame': '1 month', 'description': 'Determination of adverse effects associated with the therapy'}, {'measure': 'Adverse effects associated with the therapy', 'timeFrame': '1 year', 'description': 'Determination of adverse effects associated with the therapy'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Diabetes Mellitus']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.', 'detailedDescription': 'The purpose of this study is to determine the safety and tolerability of the administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides in patients with type 1 diabetes mellitus.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Clinical diagnosis of Type 1 Diabetes Mellitus\n* The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation\n* Written informed consent\n\nExclusion Criteria:\n\n* The presence of any malignant tumor within the last 5 years\n* Acute or chronic diseases in the stage of decompensation\n* Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis\n* Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods\n* Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol\n* Patients are unable or unwilling to give written informed consent and / or follow research procedures\n* Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study'}, 'identificationModule': {'nctId': 'NCT05207995', 'briefTitle': 'The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus'}, 'officialTitle': 'A Phase ½ Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells in Patients With Type 1 Diabetes Mellitus', 'orgStudyIdInfo': {'id': 'IBCE_DM'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells', 'description': 'Group 1: Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells', 'interventionNames': ['Biological: Autologous tolerogenic dendritic cells', 'Other: Standard treatment according to the clinical protocols']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Patients with Type 1 Diabetes Mellitus receiving standard treatment', 'description': 'Group 2: Patients with Type 1 Diabetes Mellitus receiving standard treatment', 'interventionNames': ['Other: Standard treatment according to the clinical protocols']}], 'interventions': [{'name': 'Autologous tolerogenic dendritic cells', 'type': 'BIOLOGICAL', 'description': 'Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.', 'armGroupLabels': ['Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells']}, {'name': 'Standard treatment according to the clinical protocols', 'type': 'OTHER', 'description': 'Standard treatment of type 1 diabetes mellitus according to the clinical protocols', 'armGroupLabels': ['Patients with Type 1 Diabetes Mellitus receiving standard treatment', 'Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells']}]}, 'contactsLocationsModule': {'locations': [{'zip': '220000', 'city': 'Minsk', 'country': 'Belarus', 'facility': 'Healthcare institution "Minsk City Clinical Endocrinology Center"', 'geoPoint': {'lat': 53.90019, 'lon': 27.56653}}], 'overallOfficials': [{'name': 'antonevich.n@gmail.com Antonevich, Dr', 'role': 'STUDY_DIRECTOR', 'affiliation': 'the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus'}, {'name': 'Tatiana Mokhort, Prof', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Belarusian State Medical University'}, {'name': 'Andrei Y Hancharou, Dr.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'The Institute for Biophysics and Cell Engineering of the NAS of Belarus'}, {'name': 'Yana S Minich', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Institute for Biophysics and Cell Engineering of the NAS of Belarus'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Belarusian State Medical University', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}